Frunevetmab
Frunevetmab (pronounced: froo-nev-et-mab) is a monoclonal antibody designed for the treatment of osteoarthritis in cats. It is a novel therapeutic agent that targets and neutralizes nerve growth factor (NGF), a key player in the pain pathway.
Etymology
The name "Frunevetmab" is derived from the combination of the prefix "fru-", which is an abbreviation for "feline" (referring to cats), and "-nevetmab", a common suffix for monoclonal antibodies. The "-mab" suffix is derived from the term "monoclonal antibody".
Mechanism of Action
Frunevetmab works by binding to and neutralizing nerve growth factor (NGF), a protein that plays a crucial role in the transmission of pain signals in the body. By blocking NGF, frunevetmab can help to reduce the pain associated with osteoarthritis in cats.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Osteoarthritis: A type of arthritis that occurs when flexible tissue at the ends of bones wears down.
- Nerve Growth Factor (NGF): A protein that is important for the growth, maintenance, and survival of certain nerve cells (neurons).
See Also
External links
- Medical encyclopedia article on Frunevetmab
- Wikipedia's article - Frunevetmab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski